
Oncologist

No OPD information available
EGFR Positive Lung Cancer
Lung Cancer
Mesothelioma
Non-Small Cell Lung Cancer (NSCLC)
Acute Tubular Necrosis
Anal Cancer
Constrictive Pericarditis
Ebstein's Anomaly
Familial Colorectal Cancer
Gastrointestinal Perforation
Interstitial Nephritis
Lung Adenocarcinoma
Lynch Syndrome
Melanoma
Melasma
Meningitis
Pericarditis
Peutz-Jeghers Syndrome
Pneumonia
Small Cell Lung Cancer (SCLC)
Tissue Biopsy
Thomas J. John is a male medical professional who helps patients with various health conditions like lung cancer, mesothelioma, and pneumonia. He is skilled in performing tissue biopsies to diagnose diseases accurately.
Patients trust Thomas J. John because he communicates effectively and compassionately with them. He listens to their concerns and explains medical information in a way that is easy to understand. Patients appreciate his caring and supportive approach to their treatment.
Thomas J. John stays updated with the latest medical knowledge and research to provide the best possible care to his patients. He attends conferences, reads medical journals, and collaborates with other experts in the field to ensure that he is offering the most advanced treatments available.
In his work, Thomas J. John collaborates closely with colleagues and other medical professionals. He values teamwork and believes that working together leads to better outcomes for patients. His colleagues respect him for his expertise and dedication to improving patient care.
Thomas J. John's work has positively impacted many patients' lives. Through his research and clinical practice, he has contributed to advancements in the treatment of lung cancer and other diseases. His dedication to improving patient outcomes has earned him recognition in the medical community.
One of Thomas J. John's notable publications is "Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer." This publication highlights his contributions to the field of precision oncology.
Additionally, Thomas J. John is involved in a clinical trial called "An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements." This trial aims to improve treatment options for patients with specific genetic mutations.
Overall, Thomas J. John is a dedicated and knowledgeable medical professional who is committed to providing high-quality care to his patients and advancing medical research to improve outcomes for those with serious illnesses.
Enrollment Status: Active not recruiting
Published: March 17, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
